Prostaglandin F2-alpha (PGF2α) in Vitiligo

NCT ID: NCT03755830

Last Updated: 2018-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-31

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

study the cutaneous expression of PGF2α in vitiligo patients and compare it with normal control subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitiligo patients

Two skin biopsies (lesional and non-lesional) will be taken from every patient.

Group Type ACTIVE_COMPARATOR

Skin biopsy

Intervention Type OTHER

Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.

healthy controls

A skin biopsy will be taken from each control subject.

Group Type EXPERIMENTAL

Skin biopsy

Intervention Type OTHER

Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin biopsy

Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with non-segmental vitiligo.
* Both sexes.
* Age \< 18 years old.
* New cases or cases not receiving any medications for at least 3 months ago.

Exclusion Criteria

* Age: Patients \< 18 years.
* Segmental or universal vitiligo.
* Pregnant and lactating females.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maha Fathy Elmasry

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dermatology 10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Leucotrichia in Vitiligo
NCT03402633 COMPLETED